Intrexon Corporation (XON) Receives “Buy” Rating from Griffin Securities
Griffin Securities reiterated their buy rating on shares of Intrexon Corporation (NYSE:XON) in a report released on Friday morning. Griffin Securities currently has a $55.00 price target on the biotechnology company’s stock.
Several other analysts also recently commented on XON. Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a buy rating in a report on Monday, August 7th. JMP Securities reiterated an outperform rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday. BidaskClub downgraded shares of Intrexon Corporation from a hold rating to a sell rating in a report on Friday, August 4th. Finally, Zacks Investment Research downgraded shares of Intrexon Corporation from a hold rating to a sell rating in a report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $43.20.
Shares of Intrexon Corporation (NYSE XON) traded down 5.98% on Friday, hitting $19.17. 1,150,135 shares of the stock were exchanged. The stock’s 50-day moving average is $19.08 and its 200-day moving average is $21.09. The stock’s market cap is $2.31 billion. Intrexon Corporation has a 1-year low of $17.04 and a 1-year high of $32.90.
Intrexon Corporation (NYSE:XON) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.42) earnings per share. Analysts forecast that Intrexon Corporation will post ($0.87) earnings per share for the current year.
In related news, CEO Randal J. Kirk purchased 132,625 shares of Intrexon Corporation stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average price of $18.85 per share, for a total transaction of $2,499,981.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert B. Shapiro purchased 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 144,569 shares of company stock valued at $2,719,429. 55.10% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its position in Intrexon Corporation by 2,031.7% during the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 4,937 shares during the period. Federated Investors Inc. PA bought a new position in Intrexon Corporation during the second quarter valued at about $172,000. Pacer Advisors Inc. grew its position in Intrexon Corporation by 21.6% during the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares during the period. SG Americas Securities LLC bought a new position in Intrexon Corporation during the first quarter valued at about $164,000. Finally, Cullinan Associates Inc. bought a new position in Intrexon Corporation during the second quarter valued at about $201,000. Institutional investors own 82.11% of the company’s stock.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.